Revance Therapeutics Inc(RVNC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RVNC Revance Therapeutics Inc

休市中 05-31 16:00:00 EDT

2.84

-0.05

-1.73%

盘后2.80

-0.04-1.41%

19:56 EDT

最高3.00	最低2.81	成交量193.94万
今开2.89	昨收2.89	日振幅6.57%
总市值2.97亿	流通市值2.38亿	总股本1.04亿
成交额553.04万	换手率2.32%	流通股本8,366万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"RVNC","market":"US","secType":"STK","nameCN":"Revance Therapeutics Inc","latestPrice":2.84,"timestamp":1717185600000,"preClose":2.89,"halted":0,"volume":1939396,"hourTrading":{"tag":"盘后","latestPrice":2.8,"preClose":2.84,"latestTime":"19:56 EDT","volume":48303,"amount":137312.4625,"timestamp":1717199773625},"delay":0,"floatShares":83658048,"shares":104448502,"eps":-3.635631,"marketStatus":"休市中","marketStatusCode":7,"change":-0.05,"latestTime":"05-31 16:00:00 EDT","open":2.89,"high":3,"low":2.81,"amount":5530350.603263999,"amplitude":0.065744,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.635631,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1717401600000},"adr":0,"listingDate":1391662800000,"adjPreClose":2.89,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":2.86,"preClose":2.89,"latestTime":"09:14 EDT","volume":596,"amount":1722.990108,"timestamp":1717161271307},"postHourTrading":{"tag":"盘后","latestPrice":2.8,"preClose":2.84,"latestTime":"19:56 EDT","volume":48303,"amount":137312.4625,"timestamp":1717199773625},"volumeRatio":0.9181322838316042},"requestUrl":"/m/hq/s/RVNC/wiki","defaultTab":"wiki","newsList":[{"id":"2436358181","title":"Revance Therapeutics, Inc.2024财年第一财季实现净利润-49.53百万美元，同比增加17.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436358181","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2436358181?lang=zh_cn&edition=full","pubTime":"2024-05-19 00:18","pubTimestamp":1716049087,"startTime":"0","endTime":"0","summary":"3月31日，Revance Therapeutics, Inc.公布财报，公告显示公司2024财年第一财季净利润为-49.53百万美元，同比增加17.16%；其中营业收入为51.94百万美元，同比增加5.29%，每股基本收益为-0.58美元。从资产负债表来看，Revance Therapeutics, Inc.总负债6.07亿美元，其中短期债务12.13百万美元，资产负债比为0.84，流动比率为0.06。机构评级：截至2024年3月31日，当前有11家机构对Revance Therapeutics, Inc.目标价做出预测，其中目标均价为12.82美元，其中最低目标价为6.00美元，最高目标价为25.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190018198b15ecb6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405190018198b15ecb6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435519352","title":"Revance Therapeutics, Inc.盘中异动 早盘快速上涨6.02%报3.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435519352","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435519352?lang=zh_cn&edition=full","pubTime":"2024-05-14 21:30","pubTimestamp":1715693452,"startTime":"0","endTime":"0","summary":"北京时间2024年05月14日21时30分，Revance Therapeutics, Inc.股票出现异动，股价大幅上涨6.02%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。消息层面，截至21时30分，Revance Therapeutics, Inc.股票正面舆情新闻比例16.67%。该信息摘要如下：HC Wainwright & Co.：维持Revance Therapeutics评级，由买入调整至买入评级, 目标价由12.00美元调整至11.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051421305287e87cab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051421305287e87cab&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435337386","title":"Revance Therapeutics, Inc.盘中异动 早盘快速拉升5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2435337386","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435337386?lang=zh_cn&edition=full","pubTime":"2024-05-13 21:36","pubTimestamp":1715607362,"startTime":"0","endTime":"0","summary":"北京时间2024年05月13日21时36分，Revance Therapeutics, Inc.股票出现波动，股价急速拉升5.12%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.92%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。消息层面，截至21时36分，Revance Therapeutics, Inc.股票正面舆情新闻比例16.67%。该信息摘要如下：瑞穗银行：维持Revance Therapeutics评级，由中性调整至中性评级, 目标价由9.00美元调整至8.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405132136027a599ab0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405132136027a599ab0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434853631","title":"瑞穗银行：维持Revance Therapeutics(RVNC.US)评级，由中性调整至中性评级, 目标价由9.00美元调整至8.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434853631","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2434853631?lang=zh_cn&edition=full","pubTime":"2024-05-10 20:15","pubTimestamp":1715343327,"startTime":"0","endTime":"0","summary":"瑞穗银行：维持Revance Therapeutics(RVNC.US)评级，由中性调整至中性评级, 目标价由9.00美元调整至8.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405102015298750bc79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405102015298750bc79&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433875785","title":"Revance Therapeutics Inc    预计每股亏损 75 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2433875785","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2433875785?lang=zh_cn&edition=full","pubTime":"2024-05-08 08:07","pubTimestamp":1715126843,"startTime":"0","endTime":"0","summary":"   * Revance Therapeutics Inc    将于5月9日发布截至2024年3月31日的季度业绩报告，预计该公司的季度收入将有所增长。* 根据LSEG的数据，7位分析师的平均预期显示，这家总部位于田纳西州纳什维尔的公司的营收有望从去年同期的4933万美元增长14.8%，达到5663.4万美元。* LSEG 分析师对 Revance Therapeutics Inc 的平均预期是每股亏损 75 美分。* 华尔街对 Revance Therapeutics Inc 的 12 个月目标价中位数为 12.00 美元，高于其上次收盘价 4.38 美元。5月8日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433873568","title":"Revance Therapeutics, Inc.盘中异动 大幅上涨5.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433873568","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433873568?lang=zh_cn&edition=full","pubTime":"2024-05-08 02:07","pubTimestamp":1715105253,"startTime":"0","endTime":"0","summary":"北京时间2024年05月08日02时07分，Revance Therapeutics, Inc.股票出现波动，股价快速上涨5.61%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.82%。其相关个股中，Revelation Biosciences Inc C/Wts 10/01/2027 、Lexaria Bioscience Corp C/Wts 14/01/2026 、Carmell Corp C/Wts 12/07/2028 涨幅较大，Clearmind Medicine Inc.、Allarity Therapeutics, Inc.、Tc Biopharm  Plc较为活跃，换手率分别为1460.73%、263.66%、193.57%，振幅较大的相关个股有Revelation Biosciences Inc C/Wts 10/01/2027 、Psyence Biomedical Ltd C/Wts 25/01/2029、Avenue Therapeutics, Inc.，振幅分别为96.50%、56.63%、42.73%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240508020734861eb867&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240508020734861eb867&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432236153","title":"Revance Therapeutics Inc    预计每股亏损 75 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2432236153","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432236153?lang=zh_cn&edition=full","pubTime":"2024-05-04 06:15","pubTimestamp":1714774506,"startTime":"0","endTime":"0","summary":"   * Revance Therapeutics Inc    将于5月9日发布截至2024年3月31日的季度业绩报告，预计该公司的季度收入将有所增长。* 根据LSEG的数据，7位分析师的平均预期显示，这家总部位于田纳西州纳什维尔的公司的营收有望从去年同期的4933万美元增长14.8%，达到5663.4万美元。* LSEG 分析师对 Revance Therapeutics Inc 的平均预期是每股亏损 75 美分。* 华尔街对 Revance Therapeutics Inc 的 12 个月目标价中位数为 12.00 美元，高于其上次收盘价 3.95 美元。5月3日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432970259","title":"Revance Therapeutics, Inc.盘中异动 大幅上涨5.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432970259","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432970259?lang=zh_cn&edition=full","pubTime":"2024-05-03 21:30","pubTimestamp":1714743048,"startTime":"0","endTime":"0","summary":"北京时间2024年05月03日21时30分，Revance Therapeutics, Inc.股票出现异动，股价大幅拉升5.57%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Vaxxinity, Inc.、Ardelyx, Inc.、Jaguar Health, Inc.涨幅较大，Allarity Therapeutics, Inc.、Vaxxinity, Inc.、Jaguar Health, Inc.较为活跃，换手率分别为57.88%、20.98%、10.03%，振幅较大的相关个股有Relay Therapeutics, Inc.、Rani Therapeutics Holdings, Inc.、Zymeworks Inc.，振幅分别为13.56%、12.87%、6.37%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240503213049861ead19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240503213049861ead19&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431286758","title":"Revance Therapeutics, Inc.盘中异动 早盘急速拉升5.00%报3.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431286758","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431286758?lang=zh_cn&edition=full","pubTime":"2024-04-29 22:13","pubTimestamp":1714400010,"startTime":"0","endTime":"0","summary":"北京时间2024年04月29日22时13分，Revance Therapeutics, Inc.股票出现异动，股价大幅拉升5.00%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.01%。其相关个股中，Nkgen Biotech Inc C/Wts 31/05/2028、Soleno Therapeutics, Inc.、Genenta Science Spa涨幅较大，Zyversa Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Avenue Therapeutics, Inc.较为活跃，换手率分别为871.99%、33.52%、17.48%，振幅较大的相关个股有Cassava Sciences Inc C/Wts 15/11/2024、Zyversa Therapeutics, Inc.、Immunitybio, Inc.，振幅分别为33.33%、31.06%、29.01%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240429221330861ea1b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240429221330861ea1b7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430203767","title":"Revance Therapeutics, Inc.盘中异动 早盘股价大涨5.17%报3.46美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430203767","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430203767?lang=zh_cn&edition=full","pubTime":"2024-04-26 22:10","pubTimestamp":1714140645,"startTime":"0","endTime":"0","summary":"北京时间2024年04月26日22时10分，Revance Therapeutics, Inc.股票出现异动，股价大幅拉升5.17%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Biodexa Pharmaceuticals Plc、Cassava Sciences Inc C/Wts 15/11/2024、Protagenic Therapeutics Inc C/Wts 29/04/2026 涨幅较大，Biodexa Pharmaceuticals Plc、Kintara Therapeutics, Inc.、Processa Pharmaceuticals, Inc.较为活跃，换手率分别为969.86%、96.15%、32.00%，振幅较大的相关个股有Biodexa Pharmaceuticals Plc、Cassava Sciences Inc C/Wts 15/11/2024、Tevogen Bio Holdings Inc.，振幅分别为73.12%、66.85%、30.07%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042622104687e84374&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042622104687e84374&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430501278","title":"艾伯维因 Skyrizi 销售强劲而上调年度利润预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2430501278","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430501278?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:36","pubTimestamp":1714131396,"startTime":"0","endTime":"0","summary":"艾伯维和其投资者一直关注较新的免疫学药物Skyrizi和Rinvoq的销售情况，以抵消Humira对销售额的侵蚀--Humira是全球销量最大的药物，直到去年它失去了独家代理权，并出现了近似的仿制药。Skyrizi 的销售额为 20.1 亿美元，超过了预期的 19.4 亿美元，而 Rinvoq 的销售额为 10.9 亿美元，略高于预期的 10.6 亿美元。本季度，Humira 的销售额下降了近 36%，为 22.7 亿美元，与预期的 22.8 亿美元基本一致。本季度Imbruvica的销售收入为8.38亿美元，高于预期的7.44亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430289522","title":"Revance Therapeutics, Inc.盘中异动 股价大跌5.04%报3.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430289522","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430289522?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:42","pubTimestamp":1714052536,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日21时42分，Revance Therapeutics, Inc.股票出现异动，股价大幅下挫5.04%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.36%。其相关个股中，Processa Pharmaceuticals, Inc.、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Zura Bio Limited C/Wts 涨幅较大，Processa Pharmaceuticals, Inc.、Cyclacel Pharmaceuticals, Inc.、Cidara Therapeutics, Inc.较为活跃，换手率分别为1044.08%、188.15%、7.59%，振幅较大的相关个股有Cassava Sciences Inc C/Wts 15/11/2024、Processa Pharmaceuticals, Inc.、凯信远达，振幅分别为40.85%、25.31%、14.75%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252142167a55b446&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252142167a55b446&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427873323","title":"Revance Therapeutics, Inc.盘中异动 股价大跌5.04%报3.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427873323","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427873323?lang=zh_cn&edition=full","pubTime":"2024-04-16 21:48","pubTimestamp":1713275299,"startTime":"0","endTime":"0","summary":"北京时间2024年04月16日21时48分，Revance Therapeutics, Inc.股票出现波动，股价快速跳水5.04%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.98%。其相关个股中，Jaguar Health, Inc.、Marinus Pharmaceuticals, Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 涨幅较大，Biorestorative Therapies, Inc.、Jaguar Health, Inc.、Soligenix, Inc.较为活跃，换手率分别为103.19%、42.30%、34.75%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Jaguar Health, Inc.、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025，振幅分别为101.56%、34.68%、32.06%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240416214819861e6521&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240416214819861e6521&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426731132","title":"Revance Therapeutics, Inc.盘中异动 早盘股价大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426731132","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426731132?lang=zh_cn&edition=full","pubTime":"2024-04-12 23:14","pubTimestamp":1712934858,"startTime":"0","endTime":"0","summary":"北京时间2024年04月12日23时14分，Revance Therapeutics, Inc.股票出现异动，股价急速下跌5.07%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.07%。其相关个股中，Paxmedica, Inc.、Windtree Therapeutics, Inc.、Q32 Bio Inc.涨幅较大，Allarity Therapeutics, Inc.、Paxmedica, Inc.、Aptevo Therapeutics Inc.较为活跃，换手率分别为3339.85%、1289.75%、77.87%，振幅较大的相关个股有Paxmedica, Inc.、Allarity Therapeutics, Inc.、180 Life Sciences Corp C/Wts 07/11/2025，振幅分别为75.03%、60.95%、58.59%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041223141887e7ffb0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041223141887e7ffb0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426190468","title":"Revance Therapeutics, Inc.盘中异动 早盘快速拉升5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426190468","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426190468?lang=zh_cn&edition=full","pubTime":"2024-04-09 21:57","pubTimestamp":1712671037,"startTime":"0","endTime":"0","summary":"北京时间2024年04月09日21时57分，Revance Therapeutics, Inc.股票出现异动，股价快速上涨5.28%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Acrivon Therapeutics, Inc.、Biophytis、Mymd Pharmaceuticals, Inc.涨幅较大，Mymd Pharmaceuticals, Inc.、Biophytis、Acrivon Therapeutics, Inc.较为活跃，换手率分别为376.21%、93.02%、47.81%，振幅较大的相关个股有Biophytis、Mymd Pharmaceuticals, Inc.、Cadrenal Therapeutics, Inc.，振幅分别为24.30%、22.18%、21.39%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404092157187a51a6ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404092157187a51a6ae&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424304682","title":"Revance Therapeutics, Inc.盘中异动 早盘急速下挫5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2424304682","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424304682?lang=zh_cn&edition=full","pubTime":"2024-04-02 21:51","pubTimestamp":1712065895,"startTime":"0","endTime":"0","summary":"北京时间2024年04月02日21时51分，Revance Therapeutics, Inc.股票出现异动，股价大幅下跌5.06%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.41%。其相关个股中，Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Sab Biotherapeutics Inc C/Wts 22/10/2026 、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 涨幅较大，Aditxt, Inc.、Avalo Therapeutics, Inc.、Ibio, Inc.较为活跃，换手率分别为655.04%、21.65%、15.32%，振幅较大的相关个股有Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Aditxt, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为95.84%、56.92%、41.53%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040221513587e7da27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040221513587e7da27&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revance.com","stockEarnings":[{"period":"1week","weight":0.048},{"period":"1month","weight":-0.2516},{"period":"3month","weight":-0.5931},{"period":"6month","weight":-0.6077},{"period":"1year","weight":-0.9066},{"period":"ytd","weight":-0.6769}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":0.054},{"period":"3month","weight":0.0283},{"period":"6month","weight":0.1487},{"period":"1year","weight":0.2502},{"period":"ytd","weight":0.1095}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Revance Therapeutics, Inc.于1999年8月10日成立于特拉华公司，当时名为Essentia Biosystems公司。公司是一家处于专业临床阶段的生物制药公司，专注于开发、制造和商业化用以美容和治疗的异常型肉毒杆菌毒素产品。肉毒杆菌毒素是一种良好的蛋白，目前广泛应用于美容和治疗适应症，在美国和其他国家是一个数十亿美元的市场。目前批准和商用的肉毒杆菌毒素都是注入型的。RT001, 公司的主要候选产品，是a型肉毒毒素局部配方,相对于现有注射肉毒杆菌毒素市场产品，被认为有显著的优势。公司的第二个候选产品RT002，是一种新型注射肉毒杆菌毒素类型的配方，其设计更有针对性，与其他肉毒杆菌毒素注射产品相比，更持久。这些候选产品，结合了公司的净化肉毒杆菌毒素和专有肽输送系统。公司对其两个候选产品，在全球拥有发行权利。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.017146},{"month":2,"riseRate":0.6,"avgChangeRate":0.034292},{"month":3,"riseRate":0.363636,"avgChangeRate":0.011213},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.023839},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.009304},{"month":6,"riseRate":0.7,"avgChangeRate":0.037488},{"month":7,"riseRate":0.2,"avgChangeRate":-0.025716},{"month":8,"riseRate":0.4,"avgChangeRate":-0.015335},{"month":9,"riseRate":0.5,"avgChangeRate":0.012838},{"month":10,"riseRate":0.4,"avgChangeRate":-0.075574},{"month":11,"riseRate":0.3,"avgChangeRate":-0.003095},{"month":12,"riseRate":0.6,"avgChangeRate":0.084189}],"exchange":"NASDAQ","name":"Revance Therapeutics Inc","nameEN":"Revance Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revance Therapeutics Inc(RVNC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Revance Therapeutics Inc(RVNC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Revance Therapeutics Inc,RVNC,Revance Therapeutics Inc股票,Revance Therapeutics Inc股票老虎,Revance Therapeutics Inc股票老虎国际,Revance Therapeutics Inc行情,Revance Therapeutics Inc股票行情,Revance Therapeutics Inc股价,Revance Therapeutics Inc股市,Revance Therapeutics Inc股票价格,Revance Therapeutics Inc股票交易,Revance Therapeutics Inc股票购买,Revance Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revance Therapeutics Inc(RVNC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Revance Therapeutics Inc(RVNC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}